Survodutide research and evidence overview

Survodutide has the strongest evidence base of any unapproved compound on this site: two published, randomized, double-blind, placebo-controlled phase 2 trials in peer-reviewed journals, with pre-specified endpoints and full adverse-event reporting. Both were positive. Neither is a phase 3 outcome trial, both were funded and staffed by the manufacturer, and the obesity trial had a notable dropout problem. It is a clinical-stage drug with real numbers attached — not an approved medicine, and not a research peptide with only animal data.

Survodutide (BI 456906) is a once-weekly subcutaneous dual agonist at the glucagon receptor and the GLP-1 receptor. The GLP-1 arm contributes the appetite suppression and glycaemic effects familiar from semaglutide; the glucagon arm is intended to add energy expenditure and direct hepatic effects on fat metabolism. The MASH programme exists because that second mechanism should, in principle, act on the liver in a way GLP-1 agonism alone does not.

Le Roux and colleagues ran a randomized, double-blind, placebo-controlled dose-finding trial at 43 centres in 12 countries. 387 participants were enrolled and 386 treated, randomized 1:1:1:1:1 to survodutide 0.6, 2.4, 3.6, or 4.8 mg or placebo once weekly for 46 weeks — 20 weeks of dose escalation, then 26 weeks of maintenance (Lancet Diabetes & Endocrinology, 2024).

Mean body-weight change at week 46 was −6.2% (0.6 mg), −12.5% (2.4 mg), −13.2% (3.6 mg), and −14.9% (4.8 mg). The tolerability picture is equally important: adverse events occurred in 91% of survodutide recipients versus 75% on placebo, predominantly gastrointestinal (75% vs 42%), and only 60.4% of participants completed the 46-week treatment period. The authors' conclusion was that all doses were tolerated and reduced weight dose-dependently.

Sanyal and colleagues published a 48-week phase 2 trial in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stage F1-F3, randomized 1:1:1:1 to survodutide 2.4, 4.8, or 6.0 mg or placebo (New England Journal of Medicine, 2024). 293 participants received at least one dose.

Histologic improvement in MASH without worsening of fibrosis — the primary endpoint, assessed on paired biopsy — occurred in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) of participants versus 14% on placebo. Liver fat fell by at least 30% in 57-67% of survodutide groups versus 14% on placebo. Fibrosis improved by at least one stage in 34-36% versus 22% on placebo — a much narrower margin than the steatohepatitis result, and the endpoint that matters most for long-term liver outcomes. Nausea (66% vs 23%), diarrhoea (49% vs 23%) and vomiting (41% vs 4%) were more frequent with survodutide; serious adverse events were 8% versus 7%.

Survodutide is not approved by the FDA, the EMA, or any other regulator for any indication. It is in phase 3 development by Boehringer Ingelheim in obesity and in MASH. Anything sold under this name outside a clinical trial is unapproved material of unverified identity and purity, made by a supplier with no regulatory obligation to the buyer.

• Phase 2 answers "does the mechanism do something." Phase 3 answers whether the benefit holds at scale and whether uncommon harms appear. Drugs with strong phase 2 data still fail there.
• Biopsy-defined histologic improvement is a surrogate. It has not yet been shown to translate into fewer cirrhosis, transplant, or death events for this drug.
• The 40% non-completion rate in the obesity trial makes the headline percentages less certain than they look, and reflects the real-world difficulty of tolerating a dual agonist at high doses.
• Both trials were sponsored by the manufacturer, with company employees among the authors — normal for the stage, and a reason to await independent phase 3 replication.